港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理

智通财经01-08

智通财经APP获悉，康宁杰瑞制药-B(09966)涨超6%，截至发稿，涨6.76%，报10.89港元，成交额1041.75万港元。消息面上，近日，康宁杰瑞制药-B发布公告，JSKN033(一种由抗人表皮生长因子受体2(HER2)双特异性抗体偶联药物(ADC(s))与程序性死亡配体1(PDL1)免疫检查点抑制剂组成的高浓度皮下注射复方制剂)联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2601336363?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-08 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601336363","market":"us","top_or_hot":-1,"title":"港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，康宁杰瑞制药-B(09966)涨超6%，截至发稿，涨6.76%，报10.89港元，成交额1041.75万港元。消息面上，近日，康宁杰瑞制药-B发布公告，JSKN033(一种由抗人表皮生长因子受体2(HER2)双特异性抗体偶联药物(ADC(s))与程序性死亡配体1(PDL1)免疫检查点抑制剂组成的高浓度皮下注射复方制剂)联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1390200.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-08 10:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1390200.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，康宁杰瑞制药-B(09966)涨超6%，截至发稿，涨6.76%，报10.89港元，成交额1041.75万港元。消息面上，近日，康宁杰瑞制药-B发布公告，JSKN033(一种由抗人表皮生长因子受体2(HER2)双特异性抗体偶联药物(ADC(s))与程序性死亡配体1(PDL1)免疫检查点抑制剂组成的高浓度皮下注射复方制剂)联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1390200.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IND","symbol_name":"Xtrackers Nifty 500 India ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1390200.html","article_id":"2601336363","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601336363","pubTimestamp":1767838222,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，康宁杰瑞制药-B涨超6%，截至发稿，涨6.76%，报10.89港元，成交额1041.75万港元。消息面上，近日，康宁杰瑞制药-B发布公告，JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床试验的新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IND":"Xtrackers Nifty 500 India ETF","BK1574":"生物医药B类股","BK1161":"生物科技","09966":"康宁杰瑞制药-B"},"translate_title":"Hong Kong stock changes | Corning Jerry Pharmaceuticals-B (09966) rose more than 6% Recently, an IND application for a phase II clinical trial of SKN033 was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":1.5,"IND":1.5},"content_text":"智通财经APP获悉，康宁杰瑞制药-B(09966)涨超6%，截至发稿，涨6.76%，报10.89港元，成交额1041.75万港元。消息面上，近日，康宁杰瑞制药-B发布公告，JSKN033(一种由抗人表皮生长因子受体2(HER2)双特异性抗体偶联药物(ADC(s))与程序性死亡配体1(PDL1)免疫检查点抑制剂组成的高浓度皮下注射复方制剂)联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床试验的新药临床试验(IND)申请，已获国家药品监督管理局药品审评中心(CDE)正式受理。JSKN033-202是一项开放、多中心、II期临床试验，旨在评估JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌患者的安全性、有效性及药代动力学╱药效学特征。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601336363","isCrawlerRequest":true}